An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group

Bevacizumab improves survival when added to chemotherapy in metastatic colorectal cancer (mCRC). We assessed the safety and efficacy of bevacizumab in mCRC patients ≥70 years old (YO) vs. those

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Targeted oncology 2015-03, Vol.10 (1), p.55-63
Hauptverfasser:	Tahover, Esther, Hubert, Ayala, Temper, Mark, Salah, Azzam, Peretz, Tamar, Hamburger, Tamar, Uziely, Beatrice
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - administration & dosage Bevacizumab - adverse effects Biomedicine Cohort Studies Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Disease-Free Survival Female Humans Kaplan-Meier Estimate Male Medicine Medicine & Public Health Middle Aged Neoplasm Metastasis Oncology Original Research
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Bevacizumab improves survival when added to chemotherapy in metastatic colorectal cancer (mCRC). We assessed the safety and efficacy of bevacizumab in mCRC patients ≥70 years old (YO) vs. those
ISSN:	1776-2596 1776-260X
DOI:	10.1007/s11523-014-0311-3